Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study

Rindi, Guido; Luinetti, Ombretta; Cornaggia, M; Capella, Carlo; Solcia, Enrico

doi:10.1016/0016-5085(93)90266-f

Cited by 563 publications

(584 citation statements)

References 58 publications

Supporting

Mentioning

543

Contrasting

Unclassified

Order By: Relevance

“…Gastric carcinoids are classified into three groups [9]. Type 1 gastric carcinoid is the most common (70-80% of all gastric carcinoids) and is associated with chronic atrophic gastritis.…”

Section: Introductionmentioning

confidence: 99%

Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

Essen

Krenning

Bakker

et al. 2007

Eur J Nucl Med Mol Imaging

116

View full text Add to dashboard Cite

Purpose Foregut carcinoid tumours have a different embryological origin than other gastroenteropancreatic neuroendocrine tumours (GEP NETs). In the total group of GEP NETs (n=131), treatment with 177 Lu-octreotate resulted in tumour remission in 47% of patients, with a median time to progression (TTP) of >36 months. As patients with foregut carcinoids may respond differently, we here present the effects of this treatment in a subgroup of patients with foregut carcinoids of bronchial, gastric or thymic origin. Methods Nine patients with bronchial, five with gastric and two with thymic carcinoids were treated. All patients had metastasised disease. The intended cumulative dose of 177 Lu-octreotate was 22.2-29.6 GBq. Southwest Oncology Group criteria were used for response evaluation.

show abstract

“…Gastric carcinoids are classified into three groups [9]. Type 1 gastric carcinoid is the most common (70-80% of all gastric carcinoids) and is associated with chronic atrophic gastritis.…”

Section: Introductionmentioning

confidence: 99%

Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

Essen

Krenning

Bakker

et al. 2007

Eur J Nucl Med Mol Imaging

116

View full text Add to dashboard Cite

show abstract

“…3 Some neurologic symptoms may be reversed with vitamin supplementation, depending partially on the length of time the patient experiences the symptoms. One large review documented failure of complete reversal of symptoms with vitamin B 12 replacement, yet showed improvement in frontal lobe function and language abilities. 4 Gastric carcinoids, first described by Askanazy in 1923, 5 represent an equally uncommon oncologic manifestation of both the gastric and enterochromaffin-like (ECL) tissues.…”

Section: Discussionmentioning

confidence: 99%

“…The genetic shift to hyperproliferation is thought to be related to REGl alpha gene mutation, which may normally function to suppress gastrin stimulation of ECL cells. 12 More commonly occurring in women in their sixth decade of life, type I carcinoids are typically less than 1.5 cm in size, are confined to the mucosa and submucosa in more than 90% of cases, and have a metastatic potential of less than 5%. 13 Type II carcinoids tend to be associated with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1 and are responsible for less than 10% of gastric carcinoids.…”

Section: Discussionmentioning

confidence: 99%

“…These procedures were done as both treatment of the iron deficiency anemia and prevention of further progression of the gastric carcinoid. Repeated serum laboratory testing at 3 months indicated resolution of both vitamin B 12 and iron deficiencies, as well as normalization of her previous anemia. Further, the patient's memory difficulties greatly improved, suggesting that vitamin B 12 deficiency was contributing to her cognitive impairment.…”

mentioning

confidence: 95%

“…Further, the patient's memory difficulties greatly improved, suggesting that vitamin B 12 deficiency was contributing to her cognitive impairment. The patient will be monitored with screening endoscopy every 6 months and will continue vitamin B 12 and iron supplementation.…”

mentioning

confidence: 99%

See 2 more Smart Citations

79-Year-Old Woman With Forgetfulness

Palmer

Crozier

Petrucelli

2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Treatment of Gastric Neuroendocrine Tumors

Schindl

Kaserer²,

Niederle³

2001

Arch Surg

View full text Add to dashboard Cite

Background: Gastric neuroendocrine (or gastric carcinoid) tumors have recently been classified into 3 types that differ in biological behavior and prognosis. Although the necessity of type-adapted treatment is widely accepted, it seems inconsistently used in daily practice. Hypothesis: Diagnostic differentiation into various biological types is necessary for an adequate treatment of gastric neuroendocrine tumors. Design: Retrospective study. Setting: University hospital department of surgery. Patients: Twenty-seven patients with a histologically verified gastric neuroendocrine tumor. Main Outcome Measures: A univariate analysis of survival rates with respect to tumor type, tumor biological parameters, and treatment performed was accomplished by applying the Kaplan-Meier estimation method. The log-rank test was used to evaluate the level of significance. Results: The 16 type 1 (59%) and 11 type 3 (41%) gastric neuroendocrine tumors differ in tumor size, histopathologic characteristics, and biological behavior. Nine (56%) of 16 type 1 gastric neuroendocrine tumors were treated by local excision, 8 of these (89%) had persistent atrophic gastropathy during the follow-up period. Five-year cumulative survival of patients with type 1 gastric neuroendocrine tumor was 100% without any progression into malignant phenotype. In contrast, 4 (44%) of 9 locally advanced type 3 gastricneuroendocrinetumorsweretreatedradicallybyextended resection with a 5-year cumulative survival of 75%. Conclusions: Differentiation into 3 biologically distinct tumor types for gastric neuroendocrine tumors is important with respect to therapeutic strategy and prognostic consideration. Correct diagnosis is attainable by using endoscopy, histopathologic characteristics, and laboratory chemical analysis and should precede any treatment. Extended radical surgery of high-risk type 3 tumors is indicated when definitive healing is achievable, whereas type 1 tumors are best treated by endoscopic removal and long-term follow-up.

show abstract

Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study

Cited by 563 publications

References 58 publications

Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

79-Year-Old Woman With Forgetfulness

Treatment of Gastric Neuroendocrine Tumors

Contact Info

Product

Resources

About